Skip to main content
Erschienen in: Tumor Biology 1/2016

16.08.2015 | Original Article

Gab1 regulates SDF-1-induced progression via inhibition of apoptosis pathway induced by PI3K/AKT/Bcl-2/BAX pathway in human chondrosarcoma

verfasst von: Yongqian Fan, Fengjian Yang, Xuhai Cao, Cong Chen, Xuelin Zhang, Xu Zhang, Weilong Lin, Xiaofeng Wang, Chengwei Liang

Erschienen in: Tumor Biology | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

In recent decades, the stromal cell-derived factor-l (SDF-1) and Gab1 have been investigated to be involved in oncogenesis. However, it is scarcely reported that SDF-1-Gab1 pathway mediates proliferation and apoptosis in human chondrosarcoma (CS). In this study, we assessed the expression of Gab1 in 90 CS solid tumors by immunohistochemistry, immunoblotting, and qRT-PCR, and then, some in vitro assays were also applied to CS cells treated with SDF-1. We observed that the overexpression of Gab1 was positively correlated with lung metastasis and recurrence, and acts as an independent prognostic factor for CS patients. Gab1 expression was up-regulated in response to SDF-1 stimulation in CS cell line JJ012, SW1353, L3252. Overexpression of Gab1 increased Bcl-2/BAX ratio to promote cell growth via PI3K/AKT. On the other hand, silencing of Gab1 accelerated apoptosis and repressed the growth of CS cells, which further caused the inhibition of G1/S phase transition and decreased invasion capacity in CS cell lines. In vivo assay identified that the knockdown of Gab1 interfered with the tumor mass formation. In conclusion, our data identified overexpression of Gab1 in CS tissues, and Gab1 can be recommended as a novel biomarker for diagnosis and prognosis in patients with CS. Additionally, PI3K/AKT/Bcl-2/BAX axis was involved in Gab1-induced CS progression, indicating Gab1 might act as a new target for the treatment of CS patients.
Literatur
2.
Zurück zum Zitat Azzi G, Velez M, Mathias-Machado MC. Isocitrate dehydrogenase mutations in chondrosarcoma: the crossroads between cellular metabolism and oncogenesis. Curr Opin Oncol. 2014;26:403–7.CrossRefPubMed Azzi G, Velez M, Mathias-Machado MC. Isocitrate dehydrogenase mutations in chondrosarcoma: the crossroads between cellular metabolism and oncogenesis. Curr Opin Oncol. 2014;26:403–7.CrossRefPubMed
3.
Zurück zum Zitat DeLaney TF, Liebsch NJ, Pedlow FX, et al. Long-term results of phase II study of high dose photon/proton radiotherapy in the management of spine chordomas, chondrosarcomas, and other sarcomas. J Surg Oncol. 2014;110:115–22.CrossRefPubMed DeLaney TF, Liebsch NJ, Pedlow FX, et al. Long-term results of phase II study of high dose photon/proton radiotherapy in the management of spine chordomas, chondrosarcomas, and other sarcomas. J Surg Oncol. 2014;110:115–22.CrossRefPubMed
4.
Zurück zum Zitat Frezza AM, Cesari M, Baumhoer D, et al. Mesenchymal chondrosarcoma: prognostic factors and outcome in 113 patients. A European Musculoskeletal Oncology Society study. Eur J Cancer. 2015;51:374–81.CrossRefPubMed Frezza AM, Cesari M, Baumhoer D, et al. Mesenchymal chondrosarcoma: prognostic factors and outcome in 113 patients. A European Musculoskeletal Oncology Society study. Eur J Cancer. 2015;51:374–81.CrossRefPubMed
6.
Zurück zum Zitat Yamasaki S, Nishida K, Yoshida Y, et al. Gab1 is required for EGF receptor signaling and the transformation by activated ErbB2. Oncogene. 2003;22:1546–56.CrossRefPubMed Yamasaki S, Nishida K, Yoshida Y, et al. Gab1 is required for EGF receptor signaling and the transformation by activated ErbB2. Oncogene. 2003;22:1546–56.CrossRefPubMed
7.
Zurück zum Zitat Gillgrass A, Cardiff RD, Sharan N, et al. Epidermal growth factor receptor-dependent activation of Gab1 is involved in ErbB-2-mediated mammary tumor progression. Oncogene. 2003;22:9151–5.CrossRefPubMed Gillgrass A, Cardiff RD, Sharan N, et al. Epidermal growth factor receptor-dependent activation of Gab1 is involved in ErbB-2-mediated mammary tumor progression. Oncogene. 2003;22:9151–5.CrossRefPubMed
8.
Zurück zum Zitat Seiden-Long I, Navab R, Shih W, et al. Gab1 but not Grb2mediates tumor progression in Met overexpressing colorectal cancer cells. Carcinogenesis. 2008;29:647–55.CrossRefPubMed Seiden-Long I, Navab R, Shih W, et al. Gab1 but not Grb2mediates tumor progression in Met overexpressing colorectal cancer cells. Carcinogenesis. 2008;29:647–55.CrossRefPubMed
9.
Zurück zum Zitat Sang H, Li T, Li H, et al. Down-regulation of Gab1 inhibits cell proliferation and migration in hilar cholangiocarcinoma. PLoS One. 2013;8:e81347.CrossRefPubMedPubMedCentral Sang H, Li T, Li H, et al. Down-regulation of Gab1 inhibits cell proliferation and migration in hilar cholangiocarcinoma. PLoS One. 2013;8:e81347.CrossRefPubMedPubMedCentral
10.
11.
Zurück zum Zitat Nishida K, Hirano T. The role of Gab family scaffolding adapter proteins in the signal transduction of cytokine and growth factor receptors. Cancer Sci. 2003;94:1029–33.CrossRefPubMed Nishida K, Hirano T. The role of Gab family scaffolding adapter proteins in the signal transduction of cytokine and growth factor receptors. Cancer Sci. 2003;94:1029–33.CrossRefPubMed
12.
13.
Zurück zum Zitat Shi J, Wei Y, Xia J, et al. CXCL12-CXCR4 contributes to the implication of bone marrow in cancer metastasis. Future Oncol. 2014;10(5):749–59.CrossRefPubMed Shi J, Wei Y, Xia J, et al. CXCL12-CXCR4 contributes to the implication of bone marrow in cancer metastasis. Future Oncol. 2014;10(5):749–59.CrossRefPubMed
14.
Zurück zum Zitat Nagasawa T. CXC chemokine ligand 12 (CXCL12) and its receptor CXCR4. J Mol Med (Berl). 2014;92(5):433–9.CrossRef Nagasawa T. CXC chemokine ligand 12 (CXCL12) and its receptor CXCR4. J Mol Med (Berl). 2014;92(5):433–9.CrossRef
15.
Zurück zum Zitat Yamashita J, Itoh H, Hirashima M, Ogawa M, et al. Flk1-positive cells derived from embryonic stem cells serve as vascular progenitors. Nature. 2000;408:92–6.CrossRefPubMed Yamashita J, Itoh H, Hirashima M, Ogawa M, et al. Flk1-positive cells derived from embryonic stem cells serve as vascular progenitors. Nature. 2000;408:92–6.CrossRefPubMed
16.
Zurück zum Zitat Hirakawa S, Kodama S, Kunstfeld R, et al. VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis. J Exp Med. 2005;201:1089–99.CrossRefPubMedPubMedCentral Hirakawa S, Kodama S, Kunstfeld R, et al. VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis. J Exp Med. 2005;201:1089–99.CrossRefPubMedPubMedCentral
Metadaten
Titel
Gab1 regulates SDF-1-induced progression via inhibition of apoptosis pathway induced by PI3K/AKT/Bcl-2/BAX pathway in human chondrosarcoma
verfasst von
Yongqian Fan
Fengjian Yang
Xuhai Cao
Cong Chen
Xuelin Zhang
Xu Zhang
Weilong Lin
Xiaofeng Wang
Chengwei Liang
Publikationsdatum
16.08.2015
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 1/2016
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3815-2

Weitere Artikel der Ausgabe 1/2016

Tumor Biology 1/2016 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.